![Mads Daugaard](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Mads Daugaard
President chez
RAKOVINA THERAPEUTICS INC.
Profil
Mads Daugaard is the founder of VarCT Diagnostics ApS, founded in 2017, and Var2 Pharmaceutical, founded in 2012, where the title held is Chairman.
Current jobs include Chairman at Oncomal ApS, Associate Professor at the University of British Columbia, and President & Chief Scientific Officer at Rakovina Therapeutics, Inc. since 2021.
Former job includes Head-Molecular Pathology & Cell Imaging Unit at The Vancouver Prostate Centre.
Postes actifs de Mads Daugaard
| Sociétés | Poste | Début |
|---|---|---|
| RAKOVINA THERAPEUTICS INC. | President | 01/01/2021 |
University of British Columbia
 University of British Columbia Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Var2 Pharmaceutical | Fondateur | 01/01/2012 |
VarCT Diagnostics ApS
 VarCT Diagnostics ApS VarCT Diagnostics ApS specializes in developing in vitro diagnostic assays for cancer detection and monitoring, focusing on the oncofetal chondroitin sulfate (ofcs) biomarker, which is re-expressed in most cancers but largely absent from healthy tissues except the placenta. The private company is based in Copenhagen, Denmark. The Danish company utilizes recombinant var2csa protein and proprietary high-affinity antibodies called vartumabs to detect ofcs with high sensitivity and specificity. The company's assays support early cancer detection, residual disease monitoring, and multi-cancer screening, including colorectal and bladder cancers, and they are developing immunohistochemistry companion diagnostics for tumor biopsies. VarCT Diagnostics is also advancing therapeutic applications using vartumabs-based platforms and plans a phase 0 microdosing clinical trial in 2024. The company maintains strategic collaborations with academic and industry partners internationally. The company was founded by Mads Daugaard. | Fondateur | 01/01/2017 |
Oncomal ApS
 Oncomal ApS Financial ConglomeratesFinance Functions as a financial holding company | Président | - |
Anciens postes connus de Mads Daugaard
| Sociétés | Poste | Fin |
|---|---|---|
The Vancouver Prostate Centre
 The Vancouver Prostate Centre Miscellaneous Commercial ServicesCommercial Services Provides prostate cancer research, treatment, and education services | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
93
Relations au 1er degré
6
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
University of British Columbia
University of British Columbia Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Vancouver Prostate Centre
The Vancouver Prostate Centre Miscellaneous Commercial ServicesCommercial Services Provides prostate cancer research, treatment, and education services | Commercial Services |
Rakovina Therapeutics, Inc.
 Rakovina Therapeutics, Inc. Financial ConglomeratesFinance Develops oncology therapeutics | Finance |
Var2 Pharmaceutical | |
Oncomal ApS
Oncomal ApS Financial ConglomeratesFinance Functions as a financial holding company | Finance |
VarCT Diagnostics ApS
VarCT Diagnostics ApS VarCT Diagnostics ApS specializes in developing in vitro diagnostic assays for cancer detection and monitoring, focusing on the oncofetal chondroitin sulfate (ofcs) biomarker, which is re-expressed in most cancers but largely absent from healthy tissues except the placenta. The private company is based in Copenhagen, Denmark. The Danish company utilizes recombinant var2csa protein and proprietary high-affinity antibodies called vartumabs to detect ofcs with high sensitivity and specificity. The company's assays support early cancer detection, residual disease monitoring, and multi-cancer screening, including colorectal and bladder cancers, and they are developing immunohistochemistry companion diagnostics for tumor biopsies. VarCT Diagnostics is also advancing therapeutic applications using vartumabs-based platforms and plans a phase 0 microdosing clinical trial in 2024. The company maintains strategic collaborations with academic and industry partners internationally. The company was founded by Mads Daugaard. |
